Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Sahasrabuddhe VV, Luhn P, Wentzensen N.

Future Microbiol. 2011 Sep;6(9):1083-98. doi: 10.2217/fmb.11.87. Review.

2.

Biomarkers in cervical cancer screening.

Wentzensen N, von Knebel Doeberitz M.

Dis Markers. 2007;23(4):315-30. Review.

3.

Chapter 14: Role of triage testing in cervical cancer screening.

Solomon D.

J Natl Cancer Inst Monogr. 2003;(31):97-101. Review.

PMID:
12807952
4.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
5.

Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections.

von Knebel Doeberitz M, Reuschenbach M, Schmidt D, Bergeron C.

Expert Rev Proteomics. 2012 Apr;9(2):149-63. doi: 10.1586/epr.12.13. Review.

PMID:
22462787
6.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
7.

Cervical cancer screening: on the way to a shift from cytology to full molecular screening.

Dijkstra MG, Snijders PJ, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJ.

Ann Oncol. 2014 May;25(5):927-35. doi: 10.1093/annonc/mdt538. Epub 2014 Jan 19. Review.

8.

Molecular basis for advances in cervical screening.

Doorbar J, Cubie H.

Mol Diagn. 2005;9(3):129-42. Review.

PMID:
16271014
9.

[Human papillomavirus detection in cervical cancer prevention].

Picconi MA.

Medicina (B Aires). 2013;73(6):585-96. Review. Spanish.

10.
11.

Human papillomavirus in cervical cancer screening: important role as biomarker.

Boulet GA, Horvath CA, Berghmans S, Bogers J.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):810-7. doi: 10.1158/1055-9965.EPI-07-2865. Review.

12.

Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA.

Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066. Review.

PMID:
24331747
13.

Diagnostic tests for the detection of human papillomavirus-associated cervical lesions.

Reuschenbach M, von Knebel Doeberitz M.

Curr Pharm Des. 2013;19(8):1358-70. Review.

PMID:
23016768
14.

Chapter 13: Primary screening of cervical cancer with human papillomavirus tests.

Franco EL.

J Natl Cancer Inst Monogr. 2003;(31):89-96. Review.

PMID:
12807951
15.

[Cervical cancer prevention: the impact of HPV vaccination].

Monsonégo J.

Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. Epub 2006 Mar 10. Review. French.

PMID:
16529969
16.

Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.

Dehn D, Torkko KC, Shroyer KR.

Cancer. 2007 Feb 25;111(1):1-14. Review.

17.

Human papillomavirus testing and screening.

Denny LA, Wright TC Jr.

Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):501-15. Epub 2005 Mar 16. Review.

PMID:
16150390
18.

Cervical cancer screening.

Holcomb K, Runowicz CD.

Surg Oncol Clin N Am. 2005 Oct;14(4):777-97. Review.

PMID:
16226691
19.

Human papillomavirus testing for primary cervical cancer screening.

Grce M, Davies P.

Expert Rev Mol Diagn. 2008 Sep;8(5):599-605. doi: 10.1586/14737159.8.5.599. Review.

PMID:
18785808
20.

Human papillomavirus deoxyribonucleic acid testing in developed countries.

Bhatla N, Singla S, Awasthi D.

Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):209-20. doi: 10.1016/j.bpobgyn.2011.11.003. Epub 2011 Dec 6. Review.

PMID:
22154228
Items per page

Supplemental Content

Write to the Help Desk